Unicycive Therapeutics (NASDAQ:UNCY) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reiterated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $2.50 price target on the stock. Other equities research analysts have also issued reports about the stock. Benchmark reaffirmed a speculative buy rating and issued a […]
More Stories
Blueprint Medicines (NASDAQ:BPMC) Shares Gap Up – Time to Buy?
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) gapped up before the market opened on Monday . The...
Invesco Trust for Investment Grade New York Municipals (VTN) To Go Ex-Dividend on January 17th
Invesco Trust for Investment Grade New York Municipals (NYSE:VTN – Get Free Report) declared a monthly dividend on Thursday, January...
WD-40 (WDFC) To Go Ex-Dividend on January 17th
WD-40 (NASDAQ:WDFC – Get Free Report) declared a quarterly dividend on Wednesday, December 11th,RTT News reports. Shareholders of record on...
Meridian Financial Partners LLC Takes $267,000 Position in Vanguard ESG US Stock ETF (BATS:ESGV)
Meridian Financial Partners LLC bought a new position in Vanguard ESG US Stock ETF (BATS:ESGV – Free Report) in the...
Acropolis Investment Management LLC Has $2.44 Million Stock Holdings in iShares Russell 1000 ETF (NYSEARCA:IWB)
Acropolis Investment Management LLC boosted its position in shares of iShares Russell 1000 ETF (NYSEARCA:IWB – Free Report) by 2.8%...
Acropolis Investment Management LLC Acquires 1,411 Shares of iShares ESG Aware MSCI EAFE ETF (NASDAQ:ESGD)
Acropolis Investment Management LLC increased its stake in iShares ESG Aware MSCI EAFE ETF (NASDAQ:ESGD – Free Report) by 12.8%...